MedTrace Logo

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

NCT06334133 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-04-24

No results posted yet for this study

Summary

This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

DRUG

Cadisegliatin 800 mg QD

Cadisegliatin is an orally bioavailable small-molecule glucokinase activator; adjunctive therapy to insulin.

DRUG

Cadisegliatin 800 mg BID

Cadisegliatin is an orally bioavailable small-molecule glucokinase activator; adjunctive therapy to insulin.

DRUG

Placebo

Placebo (insulin alone)

Sponsors & Collaborators

  • vTv Therapeutics

    lead INDUSTRY

Principal Investigators

  • Thomas Strack, MD · vTv Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-14
Primary Completion
2026-09-30
Completion
2026-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06334133 on ClinicalTrials.gov